Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
24/04/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
01/04/2024 | 22:15 | GlobeNewswire Inc. | Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
28/03/2024 | 14:32 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
25/03/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
21/03/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
20/03/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Selection of Two Contract Manufacturing Organizations for the Launch and Commercial Manufacture of Tonmya™ for the Management of Fibromyalgia | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
19/03/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Transition to Fully Integrated Biopharmaceutical Company Expected on April 1, 2024 | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
12/03/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Presentation at BIO-Europe Spring | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
11/03/2024 | 13:05 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
11/03/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Reports Improvement in “Brain Fog,” in Fibromyalgia Patients Treated with Tonmya™ in RESILIENT, an NDA-Enabling Phase 3 Clinical Trial, at the 6th International Congress on Controversies in Fibromyalgia | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
07/03/2024 | 15:37 | GlobeNewswire Inc. | New to The Street Announces TV Episode 560 with its Five Business Guest Interviews, Airs as Sponsored Programming on Bloomberg TV Tonight, Thursday, March 7, 2024, at 9:30 PM PT | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
07/03/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
06/03/2024 | 23:01 | Edgar (US Regulatory) | Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
06/03/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Selects EVERSANA® to Support Launch Strategy and Commercialization Planning of Tonmya™ for the Management of Fibromyalgia | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
05/03/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
29/02/2024 | 23:08 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
29/02/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Presentation at The 6th International Congress on Controversies in Fibromyalgia | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
28/02/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-modified humanized anti-CD40L mAb) in Healthy Volunteers | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
27/02/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya™ to Support Development and Partnering in Japan and China | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
23/02/2024 | 15:30 | GlobeNewswire Inc. | New to The Street Announces Line-up of its Corporate Interviews Airing on its Leadership and Business Televised Series | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
20/02/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals to Participate in the 2024 BIO CEO & Investor Conference | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
16/02/2024 | 15:30 | GlobeNewswire Inc. | New to The Street Airs Episode 556 Featuring Five Corporate Interviews, Broadcast on the FOX Business Network Monday, February 19, 2024, at 10:30 PM PT | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
14/02/2024 | 21:56 | Edgar (US Regulatory) | Form SC 13G - Statement of acquisition of beneficial ownership by individuals | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
14/02/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya™, Plans to File NDA for FDA Approval in Second Half of 2024 | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
13/02/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Engagement of Rho as CRO to Support Submission of New Drug Application to the FDA for Approval of Tonmya™ for the Management of Fibromyalgia | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
12/02/2024 | 14:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Reaction and Prevention of PTSD | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
31/01/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
29/01/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces Conditional Acceptance of Tonmya™ as Trade Name for TNX-102 SL for the Management of Fibromyalgia | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
25/01/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Announces KOL Webinar to Discuss Positive Phase 3 Fibromyalgia Data, Sponsored by A.G.P. | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |
09/01/2024 | 13:00 | GlobeNewswire Inc. | Tonix Pharmaceuticals Presents Additional Data Highlighting the Favorable Tolerability and Differentiated Side Effect Profile of TNX-102 SL in Second Positive Phase 3 Clinical Trial for the Management of Fibromyalgia | NASDAQ:TNXP | Tonix Pharmaceuticals Holding Corporation |